Regulatory updates & industry news
Tracking enforcement actions, reclassification developments, and market shifts in the peptide space.
Retatrutide Clears First Late-Stage Diabetes Trial: TRANSCEND-T2D-1 Results
Eli Lilly's triple agonist retatrutide showed A1C reductions of up to 2.0% and weight loss of up to 16.8% in the TRANSCEND-T2D-1 Phase 3 trial — with dysesthesia rates dramatically lower than TRIUMPH-4.
7 min readFirst Randomized Controlled Trial for BPC-157: What to Expect
A landmark RCT for BPC-157 began recruiting in February 2026 — the first rigorous human trial for one of the most popular peptides. Here's what it will and won't tell us.
6 min readSemaglutide Compounding Under Scrutiny: The Novo Nordisk Supply Update
As GLP-1 supply normalizes and lawsuits mount, compounded semaglutide faces an uncertain future. What consumers need to know.
7 min readFDA Enforcement and the Gray Market: What's Happening in 2026
From criminal prosecutions to warehouse raids, the FDA is cracking down on unregistered peptide sellers. A timeline of enforcement actions and what they signal.
8 min readWhat Happened to Peptide Sciences
The largest gray-market peptide vendor shut down on March 6, 2026. Here's what happened, why it matters, and what comes next.
6 min readWhat Are Compounding Pharmacies and Why Do They Matter for Peptides?
Compounding pharmacies are central to legal peptide access. Here's how they work, the 503A vs 503B distinction, and what reclassification means for the industry.
8 min readKennedy Peptide Reclassification: What Changed and What It Means
On February 27, 2026, HHS Secretary Kennedy signaled that ~14 peptides could move from Category 2 to Category 1. Here's what that means for access, clinics, and consumers.
7 min readUnderstanding Peptide Categories: FDA's Classification System Explained
The FDA's Category 1, 2, and 3 system determines which peptides can be compounded. Here's how it works, what's in each category, and why reclassification matters.
7 min read